Sanofi’s/Astazeneca’s anti-RSV antibody highly effective
NHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
The price of convenient food
A UK Biobank analysis of data from 200,000 people over more than ten years,
carried out by British researchers, have linked consumption of ultra-processed foods to an
increased risk of developing and dying from cancer. However, according to the authors from
Imperial College London it doesnt provide a causal relationship.
Mainz Biomed Partners with Microba Life Sciences
Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.
DiogenX SA raises €27.5M in Series A financing
French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Wacker AG expands biotech business through €100m acquisition
Munich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m.
BioBLU® Single-Use Bioreactors – Single-Use Simplicity
Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. Advantages like these have generated an ever-growing demand for this technology over the years. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors.
Neogap Therapeutics AB partners with Cellerys AG
Swedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.
Conflict of interest?
In 2016, PharmaMar filed a European marketing authorisation application for Aplidin as a treatment for patients with multiple myeloma. After the European Medicines Agency rejected the MAA twice, which was accepted in Australia with the same data, PharmaMar sued the EC. European Biotechnology spoke with PharmaMars Chairman José María Fernández Sousa-Faro.
Dutch State to sell share capital of Intravacc BV
The State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.